Reveal-Dx develops AI-driven decision support software that utilizes radiomics to provide non-invasive lung cancer diagnosis and malignancy scoring. This technology significantly reduces the need for invasive procedures, improving patient outcomes and lowering healthcare costs.
Funding
$4.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Lung biopsies and surgeries, often required for cancer diagnosis, carry high morbidity and mortality rates. Traditional methods for characterizing lung nodules may lead to unnecessary invasive procedures, increasing healthcare costs and negatively impacting patient outcomes.
Solution
Reveal-Dx has developed RevealAI-Lung, a CADx (computer-aided diagnosis) software that uses radiomics and AI to provide non-invasive lung nodule characterization. The software analyzes chest CT scans to compute a Malignancy Similarity Index (mSI), aiding radiologists in making patient follow-up recommendations. By integrating RevealAI-Lung into clinical workflows, healthcare providers can more effectively triage lung nodules, improve early cancer detection, and reduce false positives. The single-click operation provides actionable radiomic insights within seconds, potentially decreasing the need for invasive procedures and leading to significant cost savings.
Target Audience
The primary target audience includes radiologists and healthcare providers involved in lung cancer screening and diagnosis.
Features
- AI-driven analysis of lung nodules from chest CT scans
- Patented Malignancy Similarity Index (mSI) for nodule characterization
- Single-click operation for rapid results
- Integration with existing clinical workflows
- Technology to improve early cancer detection
- Technology to reduce false positive nodules